Abstract
Wnt5a activates the Wnt/β-catenin-independent pathway and its overexpression is associated with tumor aggressiveness enhancing invasive activity. For this action, Wnt5a-induced receptor endocytosis with clathrin is required. Wnt5a expression was previously believed to be associated with cancer cell motility but not proliferation. Recently, it was reported that Wnt5a is also implicated in cancer cell proliferation, but the mechanism was not clear. In this study, we generated a neutralizing anti-Wnt5a monoclonal antibody (mAb5A16) to investigate the mechanism by which Wnt5a regulates cancer cell proliferation. Wnt5a stimulated both invasion and proliferation of certain types of cancer cells, including HeLaS3 cervical cancer cells and A549 lung cancer cells although Wnt5a promoted invasion but not proliferation in other cancer cells such as KKLS gastric cancer cells. mAb5A16 did not affect the binding of Wnt5a to its receptor, but it suppressed Wnt5a-induced receptor-mediated endocytosis. mAb5A16 inhibited invasion but not proliferation of HeLaS3 and A549 cells. Wnt5a activated Src family kinases (SFKs) and Wnt5a-dependent cancer cell proliferation was dependent on SFKs, yet blockade of receptor-mediated endocytosis did not affect cancer cell proliferation and SFK activity. These results suggest that Wnt5a promotes invasion and proliferation of certain types of cancer cells through receptor-mediated endocytosis-dependent and -independent mechanisms, respectively.
Similar content being viewed by others
Introduction
Wnt signaling is important for various developmental processes while post-neonatal abnormalities in the signaling can result in several diseases, including cancer and bone degeneration1,2. As an extracellular ligand, Wnt activates different intracellular signaling cascades: the β-catenin-dependent and β-catenin-independent pathways3,4. In the former pathway, β-catenin is targeted for degradation after phosphorylation by the Axin complex which is composed of Axin, adenomatous polyposis coli gene product (APC) and glycogen synthase kinase 3 (GSK3)5; binding of Wnt to its receptor Frizzled (Fz) and low density lipoprotein related protein 5/6 (LRP5/6) suppresses the Axin function through caveolin-mediated receptor endocytosis, leading to the stabilization of β-catenin3,6. Cytoplasmic β-catenin translocates to the nucleus where it binds and activates the transcription factor Tcf/Lef1,2. Genetic alterations in the APC, CTNNB1 (β-catenin) and AXIN1 (Axin) genes are frequently observed in various types of cancer, including colorectal cancer and hepatocellular carcinoma7. However, the relationship between abnormalities in Wnt ligands that activate the β-catenin-dependent pathway and tumorigenicity has not yet been clarified. In contrast, Wnt5a, which activates the β-catenin-independent pathway, has been shown to exhibit elevated expression in cancer cells; elevated expression of Wnt5a is associated with progression of melanoma and lung, gastric, breast and prostate cancers8,9,10,11,12,13,14.
The β-catenin-independent pathway regulates cytoskeleton-mediated processes and polarity establishment by activating small G proteins, such as Rac and Rho, as well as certain protein kinases, including protein kinase C (PKC) and Ca2+/calmodulin kinase (CaMK)4,15. Wnt5a binds to its receptors, Fz and receptor tyrosine kinase-like orphan receptor 1/2 (Ror1/2) and induces the internalization of receptors in a clathrin-mediated manner, thereby activating Rac15,16. In melanoma, Wnt5a potentiates metastasis through the induction of epithelial mesenchymal transition in a PKC-dependent manner and expression of Wnt5a is also correlated with poor prognosis8,17. Wnt5a is expressed in tumor-associated macrophages in breast cancer13 and both Wnt5a and Wnt5b are highly expressed in cerebral metastases of breast cancer patients18. Wnt5a activates Rac and induces laminin-γ expression, thereby promoting migration and invasion in gastric cancer cells; the 5-year survival is reduced in the Wnt5a-positive gastric cancer patients10,11. Wnt5a also exhibits enhanced expression in roughly 30% of prostate cancer cases that have a high rate of relapse14. However, knockdown of Wnt5a did not affect gastric or prostate cancer cell proliferation either in vitro or in vivo10,11,14. Thus, it was previously thought that Wnt5a expression contributes to the tumor aggressiveness by enhancing cancer cell invasion and metastasis rather than by promoting cell proliferation in these cancers. Yet, it has been recently reported that Wnt5a expression is involved in proliferation of several tumor cell types, including glioma, lung cancer and T-cell leukemia19,20,21, suggesting that Wnt5a promotes cancer cell proliferation in a cell-context specific manner. However, whether the mechanism that underlies Wnt5a regulation of cancer cell proliferation is similar to the mechanism by which it regulates cancer cell migration and invasion is unknown.
An anti-Wnt5a polyclonal neutralizing antibody was generated previously, which inhibits tumor metastasis, but not proliferation, of gastric cancer cells in vivo22. Because the neutralizing activity of polyclonal antibodies varies among antibody lots, the generation of a neutralizing monoclonal antibody against Wnt5a was necessary to control quality and quantity of the antibody. The generation of a mouse anti-human Wnt5a monoclonal antibody using conventional methods did not succeed, probably due to the 100% identity between the human and mouse Wnt5a amino acid sequence23. Therefore, an anti-Wnt5a monoclonal antibody was generated using a phage library24,25,26. Using the monoclonal antibody, we demonstrated that Wnt5a stimulates both invasion and proliferation in certain types of cancer cells and that these cellular functions are distinctly regulated by receptor-mediated endocytosis-dependent and -independent manners.
Results
Generation of an anti-Wnt5a monoclonal antibody by phage library
From a 20,000 clone library, eight Wnt5a-specific clones were isolated using sequence and a phage enzyme-linked immunosorbent assay (ELISA). Treatment with the Fab fragment from E. coli expressing clone #16 (Fab16) resulted in the highest inhibition of KKLS gastric cancer cell invasion, which was dependent on endogenous Wnt5a (Supplementary Figure S1A); in addition, Wnt5a expression induced MKN-45 gastric cancer cell invasion and the Fab16 inhibited Wnt5a-dependent invasion (Supplementary Figure S1B). Fab16 was converted into rat IgG1 and this anti-Wnt5a monoclonal antibody was referred to as mAb5A16. mAb5A16 was expressed in and purified from HEK293 cells. The affinity of mAb5A16 for Wnt5a was almost identical to pAb5a-5, the rabbit polyclonal anti-Wnt5a antibody that we generated previously22 (Supplementary Figure S1C). To define the epitopes of Wnt5a recognized by mAb5A16 and pAb5a-5, 38 different 17-amino acid peptides (Pepspot), in which 7-amino acids are overlapping adjacent peptides, were generated based upon the entire human Wnt5a amino acid sequence. An epitope mapping assay showed that the predicted epitopes recognized by mAb5A16 and pAb5a-5 are the amino acids YESARIL (211–217) and RGKLVQV (281–287), respectively (Figures 1a and b).
Crystal structure analysis revealed that Xenopus Wnt8 (XWnt8) interacts with the extracellular domain of Fz8 through two sites27. One interaction (the “thumb”) is mediated by the lipid modification of XWnt8 and a groove of Fz8 and the other interaction (the “index finger”) is composed of the hydrophobic interaction between the C-terminal region of XWnt8 and a depression on Fz8 (Figure 1c). Given that human Wnt5a shows 67% amino acid similarity to XWnt8, the predicted peptides recognized by mAb5A16 and pAb5a-5 were superimposed on the three dimensional structure of XWnt8 (Figure 1c). The spatial positions of epitopes of mAb5A16 and pAb5a-5 were located close together (Figure 1c).
mAb5A16 blocks receptor-mediated endocytosis and inhibits cell migration and invasion
We previously demonstrated that pAb5a-5 inhibits Wnt5a-induced receptor endocytosis22 and that receptor-mediated endocytosis is required for Wnt5a-induced Rac1 activation and invasion ability16. In an immunocytochemical study of endocytosis, FLAG-Fz2 was localized to the cell surface membrane of KKLS cells in the absence of Wnt5a (Figures 2a and b). Wnt5a induced the internalization of FLAG-Fz2 after 30 min stimulation as the majority of cell surface localized FLAG-Fz2 disappeared (Figures 2a and b). However, after treatment with mAb5A16, Wnt5a-dependent internalization of FLAG-Fz2 was suppressed (Figures 2a and b). A cell surface biotinylation assay revealed that Wnt5a induced the internalization of endogenous Ror2 in a time-dependent manner and mAb5A16 inhibited Wnt5a-induced Ror2 internalization (Figure 2c). Consistent with these findings, mAb5A16 inhibited Wnt5a-dependent Rac1 activation (Figure 2d) as well as the in vitro invasion capability of KKLS cells with similar efficiency to pAb5a-5 (Figure 2e). KKLS cells, a highly metastatic human gastric cancer cell line, injected into the spleen of nude mice resulted in liver metastases, which were suppressed by intraperitoneal injection of mAb5A16 (Figure 2f). However, mAb5A16 did not inhibit the interaction between Wnt5a and the extracellular cysteine rich domain of Fz2 (Fz2CRD) in vitro under the conditions that secreted frizzled-related protein2 (sFRP2) suppressed their interaction28 (Supplementary Figure S1D), indicating that mAb5A16 did not affect the binding of Wnt5a to cell surface receptors but instead inhibited Wnt5a-induced receptor internalization. These results indicate that our newly generated mAb5A16 suppresses Wnt5a-dependent internalization of receptors, resulting in the prevention of gastric cancer cell metastasis by inhibiting the Rac1 activity.
Wnt5a expression promotes cancer cell proliferation
In addition to the role of Wnt5a in cell motility via cytoskeletal regulation, Wnt5a has recently been demonstrated to be involved in cell proliferation19,20,21. Wnt5a and Wnt receptor mRNA levels varied among cancer cell lines (Supplementary Figure S2A). Knockdown of Wnt5a (Supplementary Figures S2B–D) indeed suppressed proliferation of HeLaS3 cervical cancer cells as well as A549 and Calu-6 lung cancer cells (Figure 3a). Stable expression of Wnt5a (Wnt5a#8) promoted proliferation of HeLaS3 cells (Figure 3b and Supplementary Figure S2E) and rescued inhibited proliferation by depletion of Wnt5a (Figure 3b and Supplementary Figure S2F). Another Wnt5a expression clone of HeLaS3 cells (Wnt5a#9) also showed enhanced cell proliferation and did not decrease the proliferation when Wnt5a was depleted (data not shown). In addition, Wnt5a expression promoted A549 cell proliferation (Figure 3c and Supplementary Figure S2G). Knockdown of Fz2, Ror1, or Ror2 in HeLaS3 and A549 cells (Supplementary Figures S2H and I) inhibited proliferation, but Fz6 knockdown did not (Figure 3d). Cell migration and invasion were also suppressed in Wnt5a-, Ror1-, Ror2-, or Fz2-depleted HeLaS3 and A549 cells (Supplementary Figure S3), suggesting that both cell proliferation and migration capabilities of these cancer cells depend on Wnt5a signaling through its receptors. The role of Wnt5a expression in tumorigenesis in vivo was investigated by subcutaneously implanting A549 cells into the flanks of nude mice. Xenograft tumor formation was reduced by Wnt5a depletion (Figures 3e and f) and Ki67 (a cell proliferation marker) expression levels were also reduced in Wnt5a-depleted tumor cells (Figure 3g).
Proliferation of KYSE-70 and TE-11 esophageal cancer cells, in which Wnt5a was expressed at higher levels than in HeLaS3 cells (Supplementary Figure S4A), was also suppressed by knockdown of Wnt5a (Supplementary Figures S4B and C). Taken together, these results indicate that Wnt5a promotes proliferation of certain types of cancer cells in which endogenous Wnt5a is highly expressed.
Blockade of receptor-mediated endocytosis does not affect Wnt5a-induced proliferation of cancer cells
In HeLaS3 cells, mAb5A16 inhibited migration, invasion and Wnt5a-dependent activation of Rac1 (Figures 4a and b), but not cell proliferation (Figure 4c). It did not affect proliferation of A549 cells, either (data not shown). The effect of mAb5A16 on Wnt5a-induced receptor internalization in cancer cells which proliferate in a Wnt5a-dependent manner was examined. Purified Wnt5a was labelled with AlexaFluor 546 carboxylic acid succinimidyl ester to directly detect the internalization of Wnt5a. AlexaFluor 546 was conjugated to Wnt5a at a molar ratio of 3.5:1 (Supplementary Figure S5A). Although the specific activity of labelled Wnt5a (Wnt5a*) that induces the phosphorylation of Dvl2 in NIH3T3 cells was partially reduced (Supplementary Figure S5A), we used this labelling condition in the following assays because the labelling of Wnt5a with AlexaFluor 546 at a higher molar ratio (5.5-6:1) resulted in the complete loss of Wnt5a activity (Supplementary Figure S5B).
Wnt5a* was observed on HeLaS3 cell surface membranes at 4°C when FLAG-Fz2 was expressed (Figure 4d), while Wnt5a* was not observed when FLAG-Fz2 was not expressed (Figure 4e). Wnt5a* was removed from the cells by washing with an acid solution (Figure 4f), suggesting that Wnt5a* binds to the cell surface receptor. At 30 min after the temperature was shifted to 37°C, Wnt5a* disappeared from cell surface membranes and was observed as punctate structures in the cytoplasm (Figures 4g and h). Internalized Wnt5a* was co-localized with more than 80% of FLAG-Fz2 (Figures 4g and h and Supplementary Figure S5C); the complex was partially co-localized with EEA1 (Figure 4h), suggesting that Wnt5a* was internalized with FLAG-Fz2 and trafficked to the early endosomes. These results show that Wnt5a* can be used as a new tool to analyze the intracellular fate of Wnt5a after receptor binding. In the presence of mAb5A16, Wnt5a* was located to the cell surface at 4°C and most of Wnt5a* was not internalized with FLAG-Fz2 after the cells were incubated at 37°C (Figures 4i and j).
Monodansylcadavelin (MDC) promotes the assembly of clathrin, resulting in the inhibition of clathrin-dependent receptor endocytosis29. Under previous assay conditions, treatment of cells with 50 μM MDC for 30 min inhibited Wnt5a-induced Fz2 internalization and Rac1 activation16. Cells have to be treated with MDC for a long time to examine the involvement of endocytosis in cell proliferation. To avoid the cytotoxic effects induced by long-term treatment with MDC, its concentration was reduced. When HeLaS3 cells were treated with 7.5 μM MDC for 48 h, cell death was not observed as indicated using trypan blue staining assays (data not shown). Treatment of HeLaS3 cells with 7.5 μM MDC for 48 h inhibited Wnt5a-induced Fz2 internalization (Figures 5a and b) and Rac1 activation (Figure 5c). These observations were confirmed using HeLaS3 cells stably expressing Wnt5a (Wnt5a#8). Fz2 internalization was promoted in Wnt5a#8 cells as compared with control HeLaS3 cells (Control#2) and mAb5A16 and MDC inhibited Fz2 internalization in Wnt5a#8 cells (Supplementary Figure S6). In addition, MDC suppressed migration (Figure 5d) but not affected proliferation (Figure 5e) of HeLaS3 cells.
As well as HeLaS3 cells, MDC did not inhibit proliferation of A549 and Calu-6 cells (Figure 5f) under the conditions that MDC suppressed migration activity of these cancer cells (Figure 5g). Taken together, these results suggest that Wnt5a-dependent cancer cell proliferation is regulated by a receptor-mediated endocytosis-independent mechanism.
Wnt5a activated Src family kinases in a receptor-mediated endocytosis-independent manner
To understand the mechanism underlying Wnt5a-dependent cell proliferation, we analyzed several intracellular signaling molecule activities, including Src family kinases (SFKs), AKT, PKC and JNK in HeLaS3 cells. Among these signaling molecules, expression and knockdown of Wnt5a activated and inhibited, respectively, SFK activity, which was assessed by the tyrosine phosphorylation of SFK (p-SFK) (Figures 6a and b), but not other kinase activities (Supplementary Figure S7A). Src and Fyn but not Yes were expressed in HeLaS3 cells and p-SFK indeed decreased by knockdown of Src or Fyn in HeLaS3 (Supplementary Figures S7B and C). Src depletion suppressed HeLaS3 cell proliferation (Figure 6c). Knockdown of Fz2 and Ror1/2 suppressed SFK activity, but that of Fz6 did not (Figure 6d). The treatment with MDC or clathrin knockdown did not affect Wnt5a-dependent SFK activity of HeLaS3 cells (Figures 6a and b). In addition, mAb5A16 did not affect Wnt5a-induced SFK activity (Figure 6e).
Src but not Fyn or Yes was expressed in A549 and Calu-6 cells (Supplementary Figure S7B). Thus, Src was a major component of SFKs in A549 and Calu-6 cells and the SFK activity was reduced by knockdown of Wnt5a but not clathrin in these cancer cells (Supplementary Figure S7D). As well as proliferation, basal and Wnt5a-induced SFK activation in A549 and Calu-6 cells was not suppressed by MDC (Supplementary Figure S7E). These results suggest that Wnt5a-dependent SFK activation is involved in cell proliferation, but does not require receptor-mediated endocytosis.
Src depletion also inhibited the migration and invasion capabilities of HeLaS3 cells to the similar levels to Wnt5a depletion and knockdown of both Wnt5a and Src further suppressed migration and invasion (Figures 6f). Taken together with the observations that receptor-mediated endocytosis is involved in Wnt5a-dependent migration and invasion, these results suggest that Wnt5a and Src might regulate these cellular functions independently.
Discussion
In this study we generated an anti-Wnt5a monoclonal antibody (mAb5A16) from a phage library; this antibody inhibited invasion and metastasis of gastric cancer cells both in vitro and in vivo. Epitope mapping analyses revealed that mAb5A16 recognizes 211–217 amino acids of Wnt5a. Judging from the three dimensional structure of XWnt827, this region is unlikely to be involved in the binding of Wnt5a to Fz, because Wnt5a was predicted to bind to Fz through two regions that are distinct from the region recognized by mAb5A16. Consistent with these observations, mAb5A16 did not affect the binding of Wnt5a to Fz2. It was reported that Wnt3a recognizes LRP6 through the 241–263 amino acids, including acidic amino acid region30. Wnt5a has a similar acidic region that might be involved in the binding to Ror2, but the acidic region is also different from the mAb5A16 recognition region, suggesting that mAb5A16 fails to affect the binding of Wnt5a to Ror2. The region recognized by mAb5A16 was spatially close to the epitope for pAb5a-5. Similar to pAb5a-5, mAb5A16 inhibited Wnt5a-induced receptor-mediated endocytosis. Therefore, the Wnt5a regions recognized by these two antibodies could be important for Wnt5a-activated signal transduction through the receptor complex internalization.
It has been reported that glypican-4 (GPC4) overexpression in HeLaS3 cells promotes Wnt5a-induced receptor-mediated endocytosis and Rac1 activation and that Wnt5a induces the internalization of GPC4 with Fz2, followed by the localization of the complex to clathrin-positive vesicles31. Heparan sulfate proteoglycans are important for Wnt signaling and associated with developmental processes3,32. Thus, it is intriguing to speculate that the three-dimensional structure of Wnt5a, encompassing epitopes for both mAb5A16 and pAb5a-5, binds to a third factor such as GPC4, which then plays a role in Wnt5a-induced receptor-mediated endocytosis.
As a new tool to analyze Wnt5a signaling, we labelled purified Wnt5a protein using a fluorescent probe. Labelled Wnt5a (Wnt5a*) specifically bound to cell surface Fz2 and caused the internalization of Fz2. We were not able to rule out that Wnt5a* used in our experiments may be a mixture of labelled and unlabelled Wnt5a. However, because most of Wnt5a* was internalized in the presence of FLAG-Fz2 and internalized Wnt5a* was co-localized with more than 80% of FLAG-Fz2, a large part of Wnt5a could be labelled and keep the activity. Therefore, Wnt5a* is a useful tool to monitor the trafficking route of Wnt as it travels from the cell surface to intracellular destination. Using this method, the ability of mAb5A16 to inhibit Wnt5a-induced receptor internalization without affecting the binding of Wnt5a to its receptors was confirmed. Endogenous Wingless, the Drosophila Wnt homologue and endogenous Wnt5a can be detected by their antibodies in imaginal discs and mammalian cells, respectively33,34. An ectopically expressed Wnt-EGFP fusion protein was detected to be associated with microtubules in Xenopus tissue culture cells35. However, in these assays, it is hard to examine the trafficking route of Wnt and receptors. Obtaining fluorescently-tagged active Wnt proteins is challenging because covalent modification of fluorescent dyes interferes with Wnt activity. We overcame these difficulties by using our purified Wnt5a protein that has a high specific activity. Minimizing the loss of Wnt activity and enhancing the sensitivity of probe could make this method an even more powerful tool for the analysis of Wnt signaling.
Wnt5a induces clathrin-dependent receptor-mediated endocytosis, resulting in the activation of the β-catenin-independent pathway16,36, whereas Wnt3a induces caveolin-dependent receptor-mediated endocytosis, resulting in the activation of the β-catenin-dependent pathway6,37,38,39. However, the present study suggests that the endocytosis-independent mechanism exists in the β-catenin-independent pathway to regulate Wnt5a-induecd cancer cell proliferation. Although it has been shown that the Wnt5a signal is not involved in the proliferation of gastric and prostate cancer cells11,14, Wnt5a did promote the proliferation of cervical, lung and esophageal cancer cells. In the latter types of cancer cells, impairment of Wnt5a-induced receptor-mediated endocytosis by mAb5A16 or MDC did not affect cell proliferation. Although the entire mechanism by which Wnt5a stimulates cancer cell proliferation is still not fully understood, SFKs might be involved in this pathway. These experiments were done using HeLaS3 cells stably expressing Wnt5a. However, when HeLaS3 cells were stimulated with purified Wnt5a protein, SFK activation and cell proliferation were not observed (data not shown). Overexpression and knockdown of Wnt5a stimulates and inhibits, respectively, the SFK activity and cell proliferation in HeLaS3 and A549 cells. Therefore, other factors released from the cells might cooperate with Wnt5a to stimulate these cellular events. It has been reported that fluid phase and receptor-mediated endocytosis are inhibited during mitosis40, implicating that the endocytic process is not required for the control of mitotic phase. Taken together with the finding that Wnt5a-dependent cell proliferation does not require receptor internalization, it is intriguing to speculate that Wnt5a signaling promotes mitotic phase progression to stimulate cell proliferation in a receptor endocytosis-independent manner.
SFKs are localized to the inner surface of the plasma membrane and primarily transmits signals downstream of receptor tyrosine kinases (RTKs) and integrins to regulate cell proliferation, motility and survival41,42,43. Wnt5a-dependent Src activation occurs in osteosarcoma cells44, Ror2 is associated with and activates Src in melanoma cells45 and Src phosphorylation of Ror2 leads to Ror2 internalization in Rab5 positive endosomes46. The Wnt5a and Fz2 complex associates with integrin α2 to regulate focal adhesion dynamics in migrating cells47. In addition it has been recently reported that Fyn mediates Wnt5a/b- and Fz2-induced epithelial-mesenchymal transition and tumor metastasis48. Thus, SFKs are involved in the regulation of cell motility in the context of Wnt5a signaling. This study revealed that augmenting Wnt5a signaling activated Src and Fyn in HeLaS3 cells and promoted cell proliferation, but inhibition of clathrin-dependent receptor internalization did not affect the SFK activity. Therefore, Wnt5a might activate SFKs in a receptor-mediated endocytosis-independent manner, thereby stimulating proliferation. In contrast, taken together with the observations that Wnt5a-dependent migration and invasion require receptor-mediated endocytosis, Src might regulate cell migration and invasion of HeLaS3 cells in a Wnt5a-independent manner. This possibility is likely, because Src and its family are involved in the regulation of focal adhesion49,50.
mAb5A16 inhibited the invasion capability of KKLS and HeLaS3 cells to the 50–55% level (this study) and pAb5a-5 also suppressed the invasion ability of KKLS and MKN-1 cells to the 40~50% level22. Taken together with the observations that knockdown of Wnt5a reduces the invasion activity of these cancer cells to the half level, these results suggest that the signaling pathway(s) activated by molecules other than Wnt5a are involved in these cell invasion.
In the case of the β-catenin-dependent pathway, ring finger 43 (RNF43)/zinc and ring finger 3 (ZNRF3), a transmembrane E3 ligase, ubiquitinates and reduces cell surface Fz associated with LRP6, thereby suppressing intracellular signaling51,52. In the presence of R-spondin, it binds to both RNF43/ZNRF3 and leucine-rich repeat containing G protein-coupled receptor (LGR) 4/5/6 and removes RNF43/ZNRF3 from Fz, followed by the internalization of RNF43/ZNRF3 and LGR4/5/6. As a result, R-spondin acts to keep Fz on the cell surface and enhances the β-catenin-dependent signal53,54. Thus, R-spondin seems to switch and tune the signal intensity of the β-catenin-dependent pathway on cell surface by preventing the receptor internalization. Therefore, unidentified extracellular factors might activate the β-catenin-independent pathway in cooperation with Wnt5a without the receptor internalization.
In summary, we found that Wnt5a signal regulates invasion and proliferation of cancer cells through receptor-mediated endocytosis-dependent and -independent mechanisms, respectively, using our newly generated anti-Wnt5a neutralizing monoclonal antibody and labelled Wnt5a protein.
Methods
Materials and chemicals
Standard recombinant DNA techniques were used to construct pCS2/FLAG-rat Fz2 (FLAG-Fz2) and pPGK-neo/Wnt5a. pSuper-retro-GFP-Neo-shWnt5a, which was used for the generation of cells stably expressing Wnt5a shRNA, was generated by inserting small hairpin RNA against Wnt5a (5′-GTGGATAACACCTCTGTT-3′) into the pSuper-retro-GFP-Neo vector (Oligo Engine, Seattle, WA). The small interfering RNAs (siRNAs) used in this study are listed in Table S1. Wnt5a was purified to near homogeneity using three chromatography steps as described previously16,55. Anti-Wnt3a, anti-Wnt5a/b, anti-Src, anti-Fyn, anti-Yes, anti-phospho-Src family (Tyr416), anti-AKT, anti-phospho-AKT (Ser473), anti-phospho-PKC (pan) (Ser660), anti-SAPK/JNK and anti-phospho-SAPK/JNK (Thr183/Tyr185) antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-Rac1, anti-EEA1, anti-HSP90, anti-PKCα and anti-Clathrin antibodies were from BD Biosciences (San Jose, CA). Anti-FLAG M2 and anti-Ror2 antibodies were from Sigma-Aldrich (Steinheim, Germany) and R&D Systems (Minneapolis, MN), respectively.
Generation of anti-Wnt5a monoclonal antibody from the HuCAL Platinum Library
Human Wnt5a monoclonal antibodies were developed in Shionogi & Co., Ltd. The HuCAL Platinum antibody library (MorphoSys, Munic, Germany) was used for the selection of anti-Wnt5a antibodies. Anti-Wnt5a antibodies were identified by recombinant protein-based panning according to the manufacturer's instructions. His-Wnt5a, which was expressed in and purified from E. coli, was captured on Maxisorp plates (Thermo Scientific, Waltham, MA) and incubated with pools of HuCAL Platinum phage. After three rounds of selection, the enriched antibody DNA in phagemids were excised as a pool and cloned onto the expression vector pMORPHX9_Fab_FH. Fab fragments expressed from each clones were screened on His-Wnt5a-coated Maxisorp plates. Fab fragments with affinity for Wnt5a were purified and evaluated in transwell migration and invasion assays. Conversion into IgG was performed by sub-cloning variable domain fragments of heavy and light chains from Fab expression vectors into the pMORPH2_human/rat_Ig vector series to generate the anti-Wnt5a monoclonal antibody, mAb5A16. The DNA for mAb5A16 was expressed in HEK293 cells and the monoclonal antibody was subsequently purified using protein A-Sepharose.
Epitope prediction
The epitopes recognized by mAb5A16 and pAb5a-5 were predicted using a pepspot analysis according to the manufacturer's instructions (JPT Peptide Technologies, Berlin, Germany). Pepspot membrane, including of 38 peptides, each 17-amino acids in length with 7-amino acids overlapping adjacent peptides, was probed with 2 μg/ml antibody each. Bound antibodies were detected using horseradish peroxidase (HRP)-conjugated secondary antibodies and ECL™ Western blotting detection reagents (GE healthcare, Buckinghamshire, UK). Signals were detected using X-ray film (GE healthcare). All structural figures were prepared using the PyMOL Molecular Graphics System (Version 1.3r1)56.
Cell cultures
HeLaS3, A549, KYSE-70, TE-11, Calu-6 and NIH3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). KKLS and MKN-45 cells were grown in RPMI-1640 supplemented with 10% FBS. To generate HeLaS3 or MKN-45 cells stably expressing Wnt5a, HeLaS3 or MKN-45 cells were transfected with pPGK-neo/Wnt5a and selected with 400 μg/ml G418; colonies of resistant cells were isolated. Control#2 and two different HeLaS3 cell lines expressing Wnt5a (Wnt5a#8 and #9) were used in this study. To generate A549 cells stably expressing either GFP or Wnt5a, 5 × 104 parental cells/well in a 12-well plate were infected with lentiviruses expressing GFP or Wnt5a. Cells were selected and maintained in medium containing 800 μg/ml G418. To generate A549 cells stably expressing Wnt5a shRNA, A549 cells were transfected with pSuper-retro-GFP-Neo-shWnt5a and selected with 800 μg/ml G418; colonies of resistant cells were isolated. The Wnt5a-depleted cells were used in xenograft tumor assays. When necessary, the cells were treated with 7.5 μM monodansylcadaverine (MDC).
Labelling of Wnt5a
Purified Wnt5a (40 pmol) was fluorescently labelled with AlexaFluor 546 carboxylic acid succinimidyl ester (200 pmol; Life Technologies, Carlsbad, CA) in 200 mM sodium hydrogen carbonate [pH 7.4] for 3 h at 4°C. After quenching of excess AlexaFluor 546 with 300 mM hydroxylamine, labelled Wnt5a (Wnt5a*) was used for a receptor internalization assay. The degree of labelling of Wnt5a with AlexaFluor 546 was estimated by comparison to AlexaFluor 546-conjugated streptavidin (4 mol of AlexaFluor 546 conjugated to 1 mol of streptavidin, Life Technologies) using a fluorescence image analyzer (Tyhoon, GE). About 3.5 mol of AlexaFluor 546 was conjugated to 1 mol Wnt5a and Wnt5a* was used for the internalization assay.
Internalization of FLAG-Fz2 and Wnt5a*
The ligand and receptor internalization assay was performed as described previously6,16. Briefly, after KKLS, HeLaS3, or HeLaS3 cells stably expressing Wnt5a (Wnt5a#8) cells were transfected with pCS2/FLAG-Fz2, the cells were incubated with ice-cold binding medium (RPMI-1640 or DMEM containing 20 mM Hepes-NaOH [pH 7.5] and 0.1% bovine serum albumin (BSA)) for 30 min and further incubated in the presence of 500 ng/ml anti-FLAG antibody with 25 μg/ml anti-glutathione-S-transferase (GST) antibody (control Ab) or mAb5A16 for 60 min at 4°C. When necessary, the cells were treated with 100 ng/ml Wnt5a or 500 ng/ml Wnt5a* at this time. After unbound Wnt5a, Wnt5a* and antibodies were removed by washing with cold PBS three times, internalization was initiated by adding warm (37°C) RPMI-1640 (KKLS), DMEM (HeLaS3), or DMEM supplemented with 10% FBS (Wnt5a#8) and the dishes were transferred to a heated chamber (37°C, 5% CO2) for 30 or 60 min. After the cells were washed three times with cold PBS to stop endocytosis, the cells were fixed, they were probed with AlexaFluor 488-conjugated anti-mouse IgG (Life Technologies) and viewed using a confocal microscope (LSM510, Carl Zeiss, Jana, Germany) to observe FLAG-Fz2 or Wnt5a*. To quantify the distribution of FLAG-Fz2 or Wnt5a*, their localization was classified into three types as described6,16. More than 100 cells were evaluated in each experiment.
Cell proliferation assay
HeLaS3, A549, Calu-6, KYSE-70, or TE-11 cells were seeded at densities of 1 × 105/ml. HeLaS3 cells were cultured with 10% FBS while the other cells were cultured with 5% FBS. Cells were enumerated on the indicated days.
Generation of lentiviruses
Wnt5a and EGFP cDNAs were cloned into the pLVSIN-EF1α Neo Vector (Takara Bio Inc., Shiga, Japan) to construct lentivirus vectors. Lentiviruses were produced in X293T cells by using the Lenti-XTM Lentiviral Expression Systems (Takara Bio Inc.) in accordance with the manufacturer's instructions.
Enzyme-linked immunosorbent (ELISA)-based affinity assay
For the assessment of the affinity of mAb5A16 or pAb5a-5 for Wnt5a, a 96-well plate was coated with 25 μl of 2 μg/ml each antibody at 4°C overnight; the plate was then blocked with PBS containing 1% BSA for 2 h at room temperature. After blocking, 25 μl of the indicated concentrations of purified Wnt5a were added for 2 h at room temperature, washed with PBS containing 0.05% Tween-20 three times and then detected using biotinylated monoclonal anti-Wnt5a antibody (R&D Systems).
For the assessment of the ability of mAb5A16 to affect the binding of Wnt5a and Fz2, a 384 well plate was coated with 25 μl of 2 μg/ml control-IgG or 25 μl of 1 μg/ml purified Fz2CRD-IgG at 4°C overnight. The plate was blocked with PBS containing 1% BSA for 2 h at room temperature. After blocking, 25 μl of 500 ng/ml Wnt5a were added with 25 μl of 250 μg/ml anti-GST antibody (control Ab) or mAb5A16 or 25 μl of 10 μg/ml of purified sFRP2 for 2 h at room temperature, washed with PBS containing 0.05% Tween-20 three times and then detected using biotinylated monoclonal anti-Wnt5a antibody (R&D Systems).
Xenograft tumor assay
The protocols used for all animal experiments in this study were approved by the Animal Research Committee of Osaka University, Japan (No. 21-048-1). All animal experiments were carried out according to the guidelines for the care and use of experimental animals of Osaka University. The in vivo tumor metastasis assay was performed as described22 except that mAb5A16 was used. For the in vivo tumor formation assay, A549 (5 × 106) cells expressing control or Wnt5a shRNA in 100 μl of PBS were injected subcutaneously into the dorsal surfaces of nude mice through a 27-gauge needle (day 0). Five weeks after transplantation, the mice were sacrificed and the transplanted samples were measured, weighed and processed for histological analysis.
Semi-quantitative RT-PCR
Semi-quantitative RT-PCR was performed as described previously57. Forward and reverse primers are listed in Table S2.
Statistical analysis
The experiments were performed at least three times and results were expressed as the mean ± standard deviation (SD) or the mean ± standard error (SE). Differences between control and experimental groups were evaluated using the Student's t-test. A P value < 0.05 was considered a significant difference.
Others
Ror2 internalization at endogenous levels using cell surface biotinylation was examined as described previously22. Rac activity was assayed using GST-CRIB as described16,58. Quantification data was calculated based on at least three blots from different experiments. Migration capabilities of KKLS, HeLaS3 and A549 cells were measured using a modified Boyden chamber10,14. When necessary, 25 μg/ml mAb5A16, pAb5a-5, or anti-GST antibody were used. The invasive potential of the cells was analyzed using a matrigel-coated modified Boyden chamber (BD Biosciences) as described previously10,11.
References
Wodarz, A. & Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14, 59–88 (1998).
Moon, R. T., Kohn, A. D., De Ferrari, G. V. & Kaykas, A. WNT and β-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691–701 (2004).
Kikuchi, A., Yamamoto, H., Sato, A. & Matsumoto, S. New insights into the mechanism of Wnt signaling pathway activation. Int. Rev. Cell Mol. Biol. 291, 21–71 (2011).
Veeman, M. T., Axelrod, J. D. & Moon, R. T. A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell 5, 367–377 (2003).
Ikeda, S. et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J. 17, 1371–1384 (1998).
Yamamoto, H., Komekado, H. & Kikuchi, A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of β-catenin. Dev. Cell 11, 213–223 (2006).
Polakis, P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17, 45–51 (2007).
Weeraratna, A. T. et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279–288 (2002).
Kikuchi, A. & Yamamoto, H. Tumor formation due to abnormalities in the β-catenin-independent pathway of Wnt signaling. Cancer Sci. 99, 202–208 (2008).
Kurayoshi, M. et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66, 10439–10448 (2006).
Yamamoto, H. et al. Laminin γ2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology 137, 242–252 (2009).
Huang, C. L. et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor—an expression in non-small-cell lung cancer. J. Clin. Oncol. 23, 8765–8773 (2005).
Pukrop, T. et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 103, 5454–5459 (2006).
Yamamoto, H. et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29, 2036–2046 (2010).
Kikuchi, A., Yamamoto, H., Sato, A. & Matsumoto, S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol. (Oxf) 204, 17–33 (2012).
Sato, A., Yamamoto, H., Sakane, H., Koyama, H. & Kikuchi, A. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 29, 41–54 (2010).
Dissanayake, S. K. et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J. Biol. Chem. 282, 17259–17271 (2007).
Klemm, F. et al. β-Catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis 32, 434–442 (2011).
Ma, G., Yasunaga, J., Fan, J., Yanagawa, S. & Matsuoka, M. HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene 32, 4222–4230 (2013).
Huang, Y. et al. Wnt-5a regulates proliferation in lung cancer cells. Oncol. Rep. 23, 177–181 (2010).
Pulvirenti, T. et al. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res. 71, 7280–7290 (2011).
Hanaki, H. et al. An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol. Cancer Ther. 11, 298–307 (2012).
Clark, C. C. et al. Molecular cloning of the human proto-oncogene Wnt-5A and mapping of the gene (WNT5A) to chromosome 3p14-p21. Genomics 18, 249–260 (1993).
Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
Huse, W. D. et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246, 1275–1281 (1989).
McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990).
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. & Garcia, K. C. Structural basis of Wnt recognition by Frizzled. Science 337, 59–64 (2012).
Kawano, Y. & Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116, 2627–2634 (2003).
Schlegel, R., Dickson, R. B., Willingham, M. C. & Pastan, I. H. Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of α2-macroglobulin. Proc. Natl. Acad. Sci. USA. 79, 2291–2295 (1982).
Chu, M. L. et al. Structural studies of Wnts and identification of an LRP6 binding site. Structure 21, 1235–1242 (2013).
Sakane, H., Yamamoto, H., Matsumoto, S., Sato, A. & Kikuchi, A. Localization of glypican-4 in different membrane microdomains is involved in the regulation of Wnt signaling. J. Cell Sci. 125, 449–460 (2012).
Fuerer, C., Habib, S. J. & Nusse, R. A study on the interactions between heparan sulfate proteoglycans and Wnt proteins. Dev. Dyn. 239, 184–190 (2010).
Dubois, L., Lecourtois, M., Alexandre, C., Hirst, E. & Vincent, J. P. Regulated endocytic routing modulates wingless signaling in Drosophila embryos. Cell 105, 613–624 (2001).
O'Connell, M. P. et al. Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells. J. Biol. Chem. 284, 28704–28712 (2009).
Holzer, T. et al. Live imaging of active fluorophore labelled Wnt proteins. FEBS Lett. 586, 1638–1644 (2012).
Ohkawara, B., Glinka, A. & Niehrs, C. Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev. Cell 20, 303–314 (2011).
Yamamoto, H., Sakane, H., Yamamoto, H., Michiue, T. & Kikuchi, A. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of β-catenin signaling. Dev. Cell 15, 37–48 (2008).
Jiang, Y., He, X. & Howe, P. H. Disabled-2 (Dab2) inhibits Wnt/β-catenin signalling by binding LRP6 and promoting its internalization through clathrin. EMBO J. 31, 2336–2349 (2012).
Bilic, J. et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science 316, 1619–1622 (2007).
Warren, G. Membrane partitioning during cell division. Annu. Rev. Biochem. 62, 323–348 (1993).
Martin, G. S. The hunting of the Src. Nat. Rev. Mol. Cell. Biol. 2, 467–475 (2001).
Guarino, M. Src signaling in cancer invasion. J. Cell Physiol. 223, 14–26 (2010).
Saito, Y. D., Jensen, A. R., Salgia, R. & Posadas, E. M. Fyn: a novel molecular target in cancer. Cancer 116, 1629–1637 (2010).
Enomoto, M. et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28, 3197–3208 (2009).
Lai, S. S. et al. Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE. Cancer Genet. 205, 552–562 (2012).
Akbarzadeh, S. et al. The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src. PLoS One 3, e1873 (2008).
Matsumoto, S., Fumoto, K., Okamoto, T., Kaibuchi, K. & Kikuchi, A. Binding of APC and dishevelled mediates Wnt5a-regulated focal adhesion dynamics in migrating cells. EMBO J. 29, 1192–1204 (2010).
Gujral, Taranjit, S. et al. A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis. Cell 159, 844–856 (2014).
Canel, M., Serrels, A., Frame, M. C. & Brunton, V. G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J. Cell Sci. 126, 393–401 (2013).
Huveneers, S. & Danen, E. H. Adhesion signaling - crosstalk between integrins, Src and Rho. J. Cell Sci. 122, 1059–1069 (2009).
Hao, H. X. et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 485, 195–200 (2012).
Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669 (2012).
Glinka, A. et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/β-catenin and Wnt/PCP signalling. EMBO Rep. 12, 1055–1061 (2011).
de Lau, W. et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293–297 (2011).
Kurayoshi, M., Yamamoto, H., Izumi, S. & Kikuchi, A. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem. J. 402, 515–523 (2007).
Seeliger, D. & de Groot, B. L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 24, 417–422 (2010).
Hino, S., Tanji, C., Nakayama, K. I. & Kikuchi, A. Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase stabilizes β-catenin through inhibition of its ubiquitination. Mol. Cell. Biol. 25, 9063–9072 (2005).
Matsumoto, S. et al. A combination of Wnt and growth factor signaling induces Arl4c expression to form epithelial tubular structures. EMBO J. 33, 702–718 (2014).
Acknowledgements
The authors thank Drs. S. Matsumoto, S. Fujii, Y. Matsunaga and Y.J. Kim for valuable discussions regarding their technical assistance. This work was supported by Grants-in-Aid for Scientific Research to A.K. (2013–2014) (No. 25250018), A.S. (2012–2014) (No.24590378) and H.Y. (2011–2013) (No. 23590333) and (2014–2016) (No. 26460365) and for Scientific Research on Innovative Areas to A.K. (2011–2014) (No. 23112004) from the Ministry of Education, Science and Culture of Japan and by grants from the Uehara Memorial Foundation (2014).
Author information
Authors and Affiliations
Contributions
K.S. designed the experiments, carried out the mouse and cell level experiments and wrote the manuscript. A.S. designed experiments, carried out the cell level experiments and wrote the manuscript. H.H., I.T. and H.Y. carried out the mouse and cell level experiments. M.N., K.H., Y.S., K.D. and M.H. generated a neutralizing anti-Wnt5a monoclonal antibody. A.K. designed experiments and wrote the manuscript.
Ethics declarations
Competing interests
M.N., K.H., Y.S., K.D., M.H. are employees of Shionogi & Co., Ltd. A.K. has received research funds from Shionogi & Co., Ltd. All remaining authors have declared no conflicts of interest.
Electronic supplementary material
Supplementary Information
Supplementary Info
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Shojima, K., Sato, A., Hanaki, H. et al. Wnt5a promotes cancer cell invasion and proliferation by receptor-mediated endocytosis-dependent and -independent mechanisms, respectively. Sci Rep 5, 8042 (2015). https://doi.org/10.1038/srep08042
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep08042
This article is cited by
-
cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection
Cellular and Molecular Neurobiology (2023)
-
Wnt5A modulates integrin expression in a receptor-dependent manner in ovarian cancer cells
Scientific Reports (2021)
-
Overexpression of aberrant Wnt5a and its effect on acquisition of malignant phenotypes in adult T-cell leukemia/lymphoma (ATL) cells
Scientific Reports (2021)
-
The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation
Leukemia (2020)
-
Lef1 regulates caveolin expression and caveolin dependent endocytosis, a process necessary for Wnt5a/Ror2 signaling during Xenopus gastrulation
Scientific Reports (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.